Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -25.82
- Piotroski Score 4.00
- Grade Neutral
- Symbol (ACER)
- Company Acer Therapeutics Inc.
- Price $0.90
- Changes Percentage (0%)
- Change $0.9
- Day Low $0.90
- Day High $0.90
- Year High $0.90
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/19/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.93
- Trailing P/E Ratio -0.3420207253886
- Forward P/E Ratio -0.3420207253886
- P/E Growth -0.3420207253886
- Net Income $-27,860,371
Income Statement
Quarterly
Annual
Latest News of ACER
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Drag racers turn Philadelphia into a hellscape with dangerous stunts,...
Dangerous drag racers caused chaos in Philadelphia, vandalizing vehicles, setting off fireworks, and confronting police officers. The incidents were part of organized retaliation against the city's cr...
By New York Post | 1 week ago -
Macerich Meets 80-Plus Relative Strength Rating Benchmark
Discover top growth stocks using IBD's RS Rating, which measures a stock's technical performance on a scale of 1 to 99. Stocks with an RS Rating of 80 or higher tend to show strong performance. Focus ...
By Investor's Business Daily | 1 week ago -
Pacer US Small Cap Cash Cows 100 ETF (CALF) Stock Price, News, Quote & History
Investors are favoring actively-managed small-cap ETFs due to their performance and potential in a rising interest rate environment. Small-cap ETFs with high exposure to interest rate-sensitive sector...
By Yahoo! Finance | 2 weeks ago
